Case Report
Copyright ©2010 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Nov 21, 2010; 16(43): 5518-5522
Published online Nov 21, 2010. doi: 10.3748/wjg.v16.i43.5518
Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: A case report
Yubao Wang, Kermit V Speeg, William Kenneth Washburn, Glenn Halff
Yubao Wang, Division of Hematology and Medical Oncology, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, United States
Kermit V Speeg, William Kenneth Washburn, Glenn Halff, Transplant Center, School of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, United States
Author contributions: Wang Y, Speeg KV, Washburn WK and Halff G wrote the case report.
Correspondence to: Yubao Wang, MD, PhD, Assistant Professor, Division of Hematology and Medical Oncology, Department of Medicine, University of Texas Health Science Center at San Antonio, 7979 Wurzbach Road, San Antonio, TX 78229, United States. wangy5@uthscsa.edu
Telephone: +1-210-4501725 Fax: +1-210-6927502
Received: May 22, 2010
Revised: July 15, 2010
Accepted: July 22, 2010
Published online: November 21, 2010
Abstract

A case of hepatocellular carcinoma (HCC) with pulmonary recurrence after liver transplantation for HCC is presented in this report. The patient showed disease progression on sorafenib therapy demonstrated by computed tomography scans as well as serial serum α-fetoprotein (AFP) elevation. After his immunosuppression therapy was successfully transitioned to sirolimus and a continuation of sorafenib, he achieved partial remission based on RECIST criteria and normalization of AFP. Mammalian target of rapamycin inhibitors including sirolimus alone or in conjunction with sorafenib may be useful in the treatment of post transplant HCC.

Keywords: Hepatocellular carcinoma; Liver transplantation; Mammalian target of rapamycin inhibitor; Sirolimus; Sorafenib